Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score

@article{Lam2006FlapE1,
  title={Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score},
  author={John S. Lam and David B. Seligson and Hong Yu and Ai Li and Mervi Eeva and Allan J. Pantuck and Gang Zeng and Steve Horvath and Arie S. Belldegrun},
  journal={BJU International},
  year={2006},
  volume={98}
}
To investigate the expression and potential clinical usefulness of structure‐specific flap endonuclease 1 (FEN‐1) in human primary prostate cancer using tissue microarray technology, as FEN‐1 was recently identified to be overexpressed in CL1.1, the most aggressive clone generated from the hormone‐refractory prostate cancer cell line CL1. 

The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ

TLDR
FEN1 high expression in DCIS was associated with aggressive and high-risk features including higher nuclear grade, larger tumour size, comedo type necrosis, hormonal receptors negativity, higher proliferation index and triple-negative phenotype and was not an independent predictor of local recurrence-free interval.

Overexpression and Hypomethylation of Flap Endonuclease 1 Gene in Breast and Other Cancers

TLDR
It is shown that F EN1 is significantly up-regulated in multiple cancers and the aberrant expression of FEN1 is associated with hypomethylation of the CpG island within the FEN2 promoter in tumor cells.

Flap endonuclease 1 is a promising candidate biomarker in gastric cancer and is involved in cell proliferation and apoptosis.

TLDR
The results indicate that FEN1 may be a promising biomarker for the diagnosis of gastric cancer and individual therapy and a positive correlation with the degree of differentiation is confirmed.

Flap endonuclease 1 silencing is associated with increasing the cisplatin sensitivity of SGC‑7901 gastric cancer cells.

TLDR
A potential chemotherapeutic target is suggested, which exhibits enhanced sensitivity to CDDP following FEN1 silencing in SGC‑7901 cells via decreased survival and increased apoptosis.

Identification of Flap endonuclease 1 as a potential core gene in hepatocellular carcinoma by integrated bioinformatics analysis

TLDR
Nine core genes associated with HCC development are identified, offering novel insight into HCC progression, including the aberrantly elevated FEN1, which may represent a potential biomarker for HCC diagnosis and treatment.

FEN 1 is Overexpressed in Testis , Lung and Brain Tumors

TLDR
The data demonstrate that FEN1 overexpression is common in testis, lung and brain tumors and increased sensitivity to methylating agents and cisplatin in LN308 glioma cells, which indicates that altered F EN1 expression might impact the therapeutic response.

FEN1 is overexpressed in testis, lung and brain tumors.

TLDR
It is demonstrated that FEN1 overexpression is common in testis, lung and brain tumors and transiently down-regulation in the glioblastoma cell line LN308 by transfection with siRNA increased sensitivity to methylating agents and cisplatin in LN 308 glioma cells, which indicates that altered F EN1 expression might impact the therapeutic response.
...

References

SHOWING 1-10 OF 52 REFERENCES

Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone‐refractory prostate cancer tumor system

TLDR
A new hormone refractory prostate cancer cell line, CL1, derived from LNCaP via in vitro androgen deprivation is described and a pure clonal tumor system was generated to study gene expression during prostate cancer progression and to identify molecular targets for therapy.

Increased expression and no mutation of the Flap endonuclease (FEN1) gene in human lung cancer

TLDR
The results suggest that alterations of FEN1 are not likely to contribute to development of lung cancer.

Novel strategies and therapeutics for the treatment of prostate carcinoma

TLDR
An increased understanding of the biology of prostate carcinoma has led to the clinical evaluation of mechanism‐based and targeted therapies, and a variety of gene therapies has been proposed not only to replace defective genes but to localize activation of prodrugs.

Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker

TLDR
A recent analysis of results from the Prostate Cancer Prevention Trial (PCPT) has provided insight into the positive predictive value of PSA in the so‐called “normal” range.

Fen1 expression: a novel marker for cell proliferation

TLDR
Fen1 is a nuclear antigen, that it is expressed by cycling cells, and that it co‐localizes with PCNA and polymerase α during S phase, and is associated with proliferative populations in vivo and in vitro.

Haploinsufficiency of Flap endonuclease (Fen1) leads to rapid tumor progression

TLDR
Because one copy of the Fen1 gene remained intact in tumors, Fen1 haploinsufficiency appears to lead to rapid progression of cancer.
...